Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ODI Pharma ABXSAT:ODI +0.78%46 Debt-to-EBITDA is 0.00 as of Mar. 2026. GuruFocus rates XSAT:ODI with a GF Score™ of 46/100 and a GF Value™ of kr9.76 (Significantly Undervalued). Among 678 Drug Manufacturers companies, ODI Pharma AB ranks worse than 147492.48% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for ODI Pharma AB's Debt-to-EBITDA or its related term are showing as below:
XSAT:ODI's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.64 * Ranked among companies with meaningful Debt-to-EBITDA only.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
ODI Pharma AB Debt-to-EBITDA Related Terms
ODI Pharma AB Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for ODI Pharma AB's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, ODI Pharma AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ODI Pharma AB Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ODI Pharma AB's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where ODI Pharma AB's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
ODI Pharma AB (XSAT:ODI) has a Debt-to-EBITDA of 0.00 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on ODI Pharma AB. According to the industry distribution chart, ODI Pharma AB ranks #999999 out of 678 companies in the Drug Manufacturers industry.
Is ODI Pharma AB's Debt-to-EBITDA too high?
ODI Pharma AB's current Debt-to-EBITDA is 0.00. Based on the distribution chart, ODI Pharma AB ranks #999999 out of 678 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, ODI Pharma AB has a GF Score™ of 46/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ODI Pharma AB's Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ODI Pharma AB ranks #999999 out of 678 companies for Debt-to-EBITDA. This places ODI Pharma AB in the lower half of its industry. The industry median Debt-to-EBITDA is 1.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 678 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on ODI Pharma AB. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ODI Pharma AB's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ODI Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, ODI Pharma AB (XSAT:ODI) is currently considered Significantly Undervalued. The stock's GF Value™ is kr9.76, compared to a current price of kr2.58 — trading 73.6% below its estimated fair value. The current Debt-to-EBITDA is 0.00. ODI Pharma AB's overall GF Score™ is 46/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For ODI Pharma AB (XSAT:ODI), the current Debt-to-EBITDA is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ODI Pharma AB (XSAT:ODI) Overvalued in 2026?
Based on GuruFocus' analysis, ODI Pharma AB stock appears to be undervalued.
The current stock price of kr2.58 is trading 73.6% below its estimated GF Value™ of kr9.76.
GuruFocus considers ODI Pharma AB to be Significantly Undervalued.
Key valuation signals for XSAT:ODI:
Debt-to-EBITDA: 0.00
GF Value™: kr9.76 vs. price of kr2.58 (73.6% below fair value)
No single metric tells the full story. See the XSAT:ODI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:ODI has been successfully added to your 
